Methods of using SCAP antagonists
AssigneeSmithKline Beecham Corporation
InventorsThierry André Régis Grand-Perrett, Marc Issandou
Life of this patent
Estimating the term…
Abstract
The invention relates to a method for screening therapeutic agents, defined as SCAP antagonists, for use in combating diseases associated with elevated lipid levels, said method comprising detecting or assaying the extent or result of transcriptional activity or binding between a control SCAP antagonist and SCAP, in the presence of and absence of said agent. Also claimed are therapeuic agents which are antagonists of SCAP, identified by such a method and their use in combating diseases associated with elevated lipid levels.
Claims19
A method for the treatment of a mammal, having elevated circulating levels of low density lipoprotein (LDL)-cholesterol, comprising administration of an effective LDL-cholesterol lowering amount of a Sterol Responsive Element Binding Protein (SREBP)-Cleavage Activating Protein (SCAP) antagonist, or a physiologically acceptable salt or solvate thereof.
A method for reducing elevated circulating levels of low density lipoprotein (LDL) cholesterol in a mammal in need thereof, said method comprising administering to said mammal an effective LDL-cholesterol lowering amount of a compound that:
- (a) binds to Sterol Responsive Element Binding Protein—Cleaveage Activating Protein (SCAP);
- and
- (b) increases the transcription of LDL receptor, compared to the transcription that would occur in the absence of said compound.
A method of reducing elevated circulating levels of triglycerides in a mammal in need thereof, said method comprising administering to said mammal an effective triglyceride lowering amount of a compound that:
- (a) binds to Sterol Responsive Element Binding Protein—Cleaveage Activating Protein (SCAP);
- and
- (b) increases the transcription of LDL receptor, compared to the transcription that would occur in the absence of said compound.
A method for the treatment of a mammal, having elevated circulating levels of triglycerides, comprising administration of an effective triglyceride-lowering amount of a Sterol Responsive Element Binding Protein (SREBP)-Cleavage Activating Protein (SCAP) antagonist, or a physiologically acceptable salt or solvate thereof.
A method for decreasing circulating levels of low density lipoprotein (LDL)-cholesterol in a mammal in need thereof, comprising:
- a) synthesizing a SCAP antagonist suitable for administration to a mammal;
- b) preparing a pharmaceutical composition containing said SCAP antagonist;
- and
- c) administering an effective LDL-cholesterol lowering amount of said pharmaceutical composition to said mammal in need of such treatment.
A method of decreasing circulating levels of triglycerides in a mammal in need thereof, comprising:
- a) synthesizing a SCAP antagonist suitable for administration to a mammal;
- b) preparing a pharmaceutical composition containing said SCAP antagonist;
- and
- c) administering an effective triglyceride-lowering amount of said pharmaceutical composition to said mammal in need of such treatment.
Dependencies are inferred from the claim text.